Tag: MONOGRAPH

  • Canagliflozin

    Selective sodium-glucose cotransporter 2 (SGLT2) inhibitor with secondary SGLT1 inhibitory activity

    A thiophene-containing C-glucoside developed by Mitsubishi Tanabe Pharma and licensed to Janssen as the first SGLT2 inhibitor approved in the United States, distinguished by dual SGLT2/SGLT1 inhibition and landmark cardiovascular and renal outcomes evidence from the CANVAS Program and CREDENCE trial.

    Abstract

    Canagliflozin is a potent, orally bioavailable inhibitor of the sodium-glucose cotransporter 2 (SGLT2) and the first agent of its class to receive United States Food and Drug Administration approval for the treatment of type 2 diabetes mellitus. The compound acts through an insulin-independent mechanism by blocking the reabsorption of filtered glucose in the proximal tubule of the kidney, producing sustained glycosuria, reduction in plasma glucose, modest body weight loss, and reduction in systolic blood pressure. Structurally, canagliflozin is a C-glucoside bearing a thiophene ring in the aglycone region, conferring metabolic stability against glucosidase cleavage and contributing to oral bioavailability of approximately 65 percent. The inhibition constant for human SGLT2 is approximately 4.2 nM, with approximately 160-fold to 250-fold selectivity over SGLT1 (Ki approximately 710 to 910 nM), a selectivity ratio that permits modest intestinal SGLT1 inhibition at the 300 mg clinical dose, contributing to postprandial glucose lowering through delayed intestinal glucose absorption [1, 2].

    The compound was discovered at Mitsubishi Tanabe Pharma through systematic optimization of C-glucoside scaffolds for SGLT2 potency, metabolic stability, and oral pharmacokinetics [1]. Janssen Pharmaceuticals obtained development and commercialization rights through a licensing agreement and advanced canagliflozin through a comprehensive Phase 3 program (nine controlled studies, approximately 10,285 subjects) culminating in FDA approval on 29 March 2013 under the trade name Invokana [3, 4]. The compound was subsequently approved by the European Medicines Agency in November 2013 and in multiple additional jurisdictions. A fixed-dose combination with metformin (Invokamet) was approved in 2014.

    The clinical evidence base for canagliflozin extends substantially beyond glycemic control. The CANVAS Program (Canagliflozin Cardiovascular Assessment Study and CANVAS-R; N = 10,142; mean follow-up 188.2 weeks), published by Neal et al. in the New England Journal of Medicine in 2017, demonstrated a statistically significant 14 percent reduction in the composite of cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke (hazard ratio 0.86; 95 percent confidence interval 0.75 to 0.97) [5]. The CREDENCE trial (Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation; N = 4,401; median follow-up 2.62 years), published by Perkovic et al. in the New England Journal of Medicine in 2019, demonstrated a 30 percent reduction in the primary composite of end-stage kidney disease, doubling of serum creatinine, or renal or cardiovascular death (hazard ratio 0.70; 95 percent confidence interval 0.59 to 0.82), establishing canagliflozin as the first SGLT2 inhibitor with a dedicated positive renal outcomes trial [6].

    Pharmacokinetics are characterized by rapid oral absorption (time to peak 1 to 2 hours), dose-proportional exposure across a wide range (50 to 1600 mg), steady-state attainment within 4 to 5 days, and predominant elimination through hepatic O-glucuronidation by UGT1A9 and UGT2B4, producing two inactive metabolites (M5 and M7) [7]. The terminal elimination half-life is approximately 10.6 to 13.1 hours at steady state, supporting once-daily dosing. Approximately 60 percent of the administered dose is recovered in feces and 33 percent in urine. Clinically significant drug-drug interactions are limited; UGT enzyme inducers (rifampin, phenytoin, ritonavir) reduce canagliflozin exposure and may require dose adjustment.

    The safety profile includes class-related adverse events: genital mycotic infections (principally vulvovaginal candidiasis in women and balanitis in men; occurring in approximately 10 to 12 percent of patients), urinary tract infections, volume depletion events related to osmotic diuresis, and euglycemic diabetic ketoacidosis (rare but clinically significant). The CANVAS Program identified a signal for increased lower-extremity amputations (6.3 versus 3.4 per 1,000 patient-years; hazard ratio 1.97), predominantly at the toe and metatarsal level, prompting an FDA boxed warning in 2017 that was subsequently removed in 2020 after additional data, including the CREDENCE trial, did not confirm the excess risk at a comparable magnitude [5, 8]. Bone fracture risk was identified in CANVAS but not confirmed in CREDENCE. Fournier gangrene (necrotizing fasciitis of the perineum) has been reported rarely across the SGLT2 inhibitor class.

    This monograph documents the chemistry, synthesis, and structure-activity relationships of canagliflozin; the molecular pharmacology of SGLT2 and SGLT1 inhibition; the comprehensive human pharmacokinetic record; preclinical pharmacology in animal models of diabetes and kidney disease; the clinical evidence base across glycemic, cardiovascular, and renal outcomes; sourcing and quality verification for research applications; reconstitution and handling; stack-interaction considerations; adverse-event signal including the amputation and ketoacidosis findings; and a structured comparative assessment of five SGLT2 inhibitor alternatives (dapagliflozin, empagliflozin, ertugliflozin, sotagliflozin, and bexagliflozin) against canagliflozin on five competency standards: novelty, effect size, promising potential, side-effect profile, and overall validation.

    Read the full monograph

    The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

    KDC-MN-1603Open in new tab →

    Download PDF →

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

  • Hemantane

    Aminoadamantane derivative with low-affinity noncompetitive NMDA receptor antagonism, selective MAO-B inhibition, and dopaminergic modulation

    An aminoadamantane-class antiparkinsonian agent developed at the Zakusov Institute of Pharmacology in Russia, distinguished from amantadine and memantine by a hexamethylenimine substituent that confers a broader pharmacological spectrum encompassing NMDA receptor channel blockade, selective monoamine oxidase B inhibition, dopamine transporter modulation, and anti-inflammatory activity.

    Abstract

    Hemantane (N-(2-adamantyl)hexamethyleneimine hydrochloride; gimantan) is an experimental antiparkinsonian and neuroprotective agent of the aminoadamantane structural class, synthesized and developed at the V.V. Zakusov Research Institute of Pharmacology of the Russian Academy of Medical Sciences. The compound shares the adamantane cage scaffold with the clinically established agents amantadine and memantine but is distinguished by the attachment of a seven-membered azepane (hexamethylenimine) ring at the 2-position of the adamantane nucleus, a modification that broadens the pharmacological profile relative to the parent aminoadamantanes. Hemantane acts through multiple convergent mechanisms: it is a low-affinity, noncompetitive (uncompetitive) open-channel blocker of the N-methyl-D-aspartate (NMDA) subtype of the ionotropic glutamate receptor; a weak, competitive, selective inhibitor of monoamine oxidase B (MAO-B; Ki approximately 470 micromolar); a noncompetitive modulator of the dopamine transporter (DAT) that acutely reduces striatal dopamine reuptake Vmax by approximately 30 percent; a modulator of dopamine receptor subtype density (upregulating D1 and downregulating D2/D3 binding sites in the striatum after subchronic administration); and a putative sigma receptor agonist. The compound also exhibits anti-inflammatory activity in models of peripheral inflammation (acetic acid peritonitis, carrageenan-induced paw edema) and in a lipopolysaccharide-induced neuroinflammation model of Parkinson disease, where it attenuated weight loss, contralateral forepaw akinesia, and olfactory behavioral disruption.

    In preclinical parkinsonism models, hemantane (10 to 20 mg/kg intraperitoneally) reduced tremor, rigidity, and oligokinesia, and was reported to be superior to the reference drug amantadine in several behavioral paradigms. In the MPTP-treated C57BL/6 mouse model, subchronic hemantane administration increased dopamine transporter levels in multiple brain structures, a response broader than that produced by amantadine. A single administration of hemantane (20 mg/kg) in C57BL/6 mice reduced striatal DOPA concentration, decreased serotonin and its metabolite levels in the striatum, and altered the homovanillic acid to dopamine ratio in the frontal cortex, demonstrating modulatory activity across both dopaminergic and serotonergic systems.

    Clinical evaluation of hemantane has been conducted in a randomized, double-blind, placebo-controlled Phase 2 trial in 60 patients with newly diagnosed, untreated early-stage Parkinson disease over 16 weeks. Hemantane at 50 mg daily (25 mg twice daily) produced a 41 percent reduction in rigidity from baseline and statistically significant improvement on the Unified Parkinson’s Disease Rating Scale (UPDRS) Part III motor examination scores at weeks 8, 12, and 16 compared with placebo. The 25 mg daily dose produced moderate efficacy. Safety monitoring (blood pressure, electrocardiogram, blood and urine parameters) did not identify dose-limiting toxicity at either dose. Additional preclinical research has demonstrated analgesic activity in somatic and visceral pain models, efficacy in reducing ethanol consumption in alcohol-experienced rats, attenuation of morphine withdrawal signs, and anti-arthritic activity when applied as a 5 percent topical gel formulation. The compound has not received marketing authorization in any jurisdiction and remains an investigational agent. This monograph documents the chemistry, synthesis, multi-target pharmacology, preclinical and clinical evidence, sourcing considerations, and a comparative assessment of hemantane against five structurally or mechanistically related compounds on five competency standards.

    Read the full monograph

    The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

    KDC-MN-1579Open in new tab →

    Download PDF →

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

  • Halneuron

    Guanidinium alkaloid voltage-gated sodium channel blocker (tetrodotoxin formulation) for peripheral neuropathic and cancer-related pain

    A pharmaceutical-grade injectable formulation of tetrodotoxin developed by WEX Pharmaceuticals (now Dogwood Therapeutics) as a non-opioid, peripherally restricted analgesic that selectively blocks TTX-sensitive voltage-gated sodium channels on nociceptive neurons, with clinical development focused on chemotherapy-induced neuropathic pain and cancer-related pain.

    Abstract

    Halneuron is the proprietary injectable formulation of tetrodotoxin (TTX), a naturally occurring guanidinium alkaloid neurotoxin and potent, reversible blocker of TTX-sensitive voltage-gated sodium channels (VGSCs), developed by WEX Pharmaceuticals Inc. (Vancouver, British Columbia, Canada; now Dogwood Therapeutics Inc., NASDAQ: DWTX) as a non-opioid analgesic for moderate to severe neuropathic and cancer-related pain. The active pharmaceutical ingredient, tetrodotoxin (C11H17N3O8, molecular weight 319.3 g/mol, CAS 4368-28-9), blocks TTX-sensitive sodium channel subtypes NaV1.1, NaV1.2, NaV1.3, NaV1.4, NaV1.6, and NaV1.7 at low-nanomolar concentrations, with IC50 values ranging from approximately 2.3 nM (NaV1.6) to 36 nM (NaV1.7). The NaV1.7 subtype is of particular analgesic relevance: human loss-of-function mutations in SCN9A (the gene encoding NaV1.7) produce congenital insensitivity to pain, establishing the channel as a genetically validated analgesic target. Halneuron is administered by subcutaneous injection and does not cross the blood-brain barrier in pharmacologically significant quantities, conferring a safety profile that is free of the euphoria, sedation, tolerance, addiction, and cognitive impairment associated with opioid and centrally acting analgesics.

    The clinical development program has evaluated Halneuron in over 700 subjects across multiple Phase 1, Phase 2, and Phase 2b trials. The pivotal cancer pain trial (Hagen et al. 2017), a multicentre, randomized, double-blind, placebo-controlled study of 165 patients at 19 sites in Canada, Australia, and New Zealand, demonstrated a clinically significant estimated effect size of 16.2% on the pain endpoint for TTX 30 micrograms subcutaneously twice daily for four days versus placebo, with 51% of TTX-treated patients achieving 30% or greater pain reduction compared to 35% on placebo. An open-label safety and efficacy study (Hagen et al. 2011) in 77 cancer pain patients demonstrated that the analgesic effect persisted for weeks to months following a four-day treatment cycle, a finding that distinguishes TTX from conventional short-acting analgesics and suggests a disease-modifying or neuroplastic component to the mechanism. The Phase 2 dose-finding trial for chemotherapy-induced neuropathic pain (CINP; Bhatt et al. 2021) in 125 patients identified the 30 microgram twice-daily regimen as the optimal dose for further study, with cumulative responder analysis showing significant separation from placebo. The ongoing Phase 2b HALT-CINP trial, conducted at approximately 30 sites in the United States under Dogwood Therapeutics, reported positive interim results in December 2025 from 97 patients, with Halneuron-treated patients demonstrating separation from placebo on pain improvement over four weeks, a dropout rate of approximately 4.4% (substantially below rates observed with approved chronic pain agents), and encouraging safety and tolerability.

    Pharmacokinetics following subcutaneous injection are characterized by rapid absorption (time to maximum plasma concentration approximately 1.5 hours), dose-proportional exposure, and an elimination half-life of approximately 4.5 hours, with plasma concentrations falling below the limit of quantification within 24 hours. The compound is not metabolized by cytochrome P450 enzymes and does not produce the pharmacogenomic variability that complicates agents dependent on CYP2D6 or CYP3A4. Safety data from Phase 1 dose-escalation studies in healthy adults (doses of 15 to 45 micrograms subcutaneously) demonstrate that Halneuron is well tolerated, produces no QT prolongation, and carries no proarrhythmic proclivity. The most common adverse events across clinical trials are perioral paresthesia, oral numbness, headache, dizziness, nausea, and myalgia, all generally mild to moderate and self-limiting.

    This monograph reviews the chemistry, natural history, and pharmaceutical development of tetrodotoxin as Halneuron; the molecular pharmacology of TTX-sensitive sodium channel blockade with emphasis on NaV1.7; the human pharmacokinetic record; the preclinical analgesic evidence base in rodent models of neuropathic, inflammatory, and cancer pain; the complete clinical evidence base across cancer pain, chemotherapy-induced neuropathic pain, and ongoing Phase 2b trials; sourcing and quality verification; reconstitution and handling; stack-interaction considerations; adverse-event signal; and a structured comparative assessment of five alternative analgesic candidates for chemotherapy-induced neuropathic pain (duloxetine, pregabalin, vixotrigine, capsaicin 8% patch, and lidocaine 5% patch) against Halneuron on five competency standards.

    Read the full monograph

    The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

    KDC-MN-1577Open in new tab →

    Download PDF →

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

  • Procyanidin C1

    B-type proanthocyanidin trimer (oligomeric flavan-3-ol) with senolytic, senomorphic, and multi-target anti-inflammatory activity

    A naturally occurring epicatechin trimer from grape seed extract identified as a dual-mode senotherapeutic agent that selectively eliminates senescent cells at high concentrations while suppressing the senescence-associated secretory phenotype at low concentrations, with demonstrated lifespan extension in mice and emerging preclinical evidence across fibrotic, neurodegenerative, and oncologic indications.

    Abstract

    Procyanidin C1 (PCC1) is a B-type proanthocyanidin trimer composed of three (2R,3R)-(-)-epicatechin units joined by two successive (4beta to 8)-interflavan bonds, with molecular formula C45H38O18 and molecular weight 866.77 g/mol. The compound is a polyphenolic constituent of grape seed extract (GSE), cocoa, cinnamon bark, unripe apple peel, and pine bark, and was first structurally characterized in the 1980s as part of the broader oligomeric proanthocyanidin (OPC) family originally described by Masquelier in 1947. PCC1 remained a minor analytical curiosity within the proanthocyanidin literature until 2021, when a landmark screening study by Xu, Fu, and colleagues, published in Nature Metabolism, identified PCC1 as a potent and selective senotherapeutic agent capable of extending healthspan and lifespan in aged mice through dual-mode activity on senescent cells [1]. At low concentrations (below approximately 50 micromolar), PCC1 acts as a senomorphic agent, suppressing the production of pro-inflammatory senescence-associated secretory phenotype (SASP) factors through inhibition of NF-kappaB signaling without inducing senescent cell death. At higher concentrations (above approximately 100 micromolar), PCC1 transitions to a senolytic mode, selectively inducing apoptosis in senescent cells through a reactive oxygen species (ROS)-dependent mitochondrial dysfunction pathway involving the p53-Puma/Noxa axis, while sparing proliferating and quiescent non-senescent cells. This concentration-dependent functional switch distinguishes PCC1 from most other characterized senolytic agents and provides a pharmacological basis for dose-titrated senotherapeutic intervention.

    The 2021 Nature Metabolism study demonstrated that intermittent administration of PCC1 (20 mg/kg intraperitoneally, biweekly for two months) to aged C57BL/6J mice reduced senescent cell burden across multiple tissues, attenuated age-related physical dysfunction, and extended median remaining lifespan by approximately 64 percent compared to vehicle-treated controls, with no observed systemic toxicity [1]. Subsequent preclinical studies have expanded the evidence base substantially. Zhu, Huang, and colleagues (2024) demonstrated that PCC1 alleviates structural and functional decline in the aged mouse retina through combined senolytic and senomorphic mechanisms [2]. Gan and colleagues (2025) reported that PCC1 alleviates renal fibrosis by promoting apoptosis of senescent renal tubular epithelial cells [3]. Additional preclinical evidence supports activity against skin fibrosis through EGFR inhibition and TGF-beta/SMAD pathway suppression [4], neuroprotection through Nrf2/HO-1 signaling activation [5], endothelial nitric oxide production through PI3K/Akt-dependent eNOS phosphorylation [6], insulin sensitization in adipocytes through AKT-eNOS pathway activation [7], and colon cancer growth inhibition through miR-501-3p/HIGD1A axis modulation [8]. Single-cell profiling has revealed broad geroprotective effects on the hematopoietic immune system, including restoration of B cell and hematopoietic stem cell populations and suppression of senescence-associated inflammatory markers [9].

    Pharmacokinetically, PCC1 shares the absorption limitations characteristic of oligomeric proanthocyanidins: oral bioavailability of trimeric procyanidins is low, with the majority of ingested material reaching the colon intact where it is degraded by gut microbiota into phenylvalerolactones, phenylvaleric acids, and smaller phenolic acid metabolites. Phytosomal formulations have demonstrated 2- to 3-fold improvements in gastrointestinal absorption efficiency. No completed Phase 1 or Phase 2 clinical trials of purified PCC1 have been published as of the most recent monograph revision, though preliminary findings from phytosomal PCC1 formulations have shown reductions in senescence markers in peripheral blood mononuclear cells from elderly individuals. The compound is not approved by any regulatory authority for therapeutic use. It is available as a research-grade preparation from multiple chemical suppliers at greater than 95 percent purity by HPLC. This monograph documents the chemistry, natural sourcing, dual-mode senotherapeutic pharmacology, pharmacokinetics, preclinical evidence base across aging, fibrotic, neurodegenerative, metabolic, and oncologic indications, sourcing and quality verification, reconstitution and handling, stack-interaction considerations, adverse-event signal, and a structured comparative assessment of five senolytic candidates against PCC1 on five competency standards.

    Read the full monograph

    The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

    KDC-MN-1573Open in new tab →

    Download PDF →

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

  • Tetrahydropalmatine

    Tetrahydroprotoberberine isoquinoline alkaloid with multi-target dopamine receptor antagonism and analgesic, sedative, and anti-addictive activity

    A plant-derived protoberberine alkaloid from Corydalis yanhusuo and Stephania rotunda with documented dopamine D1/D2/D3 receptor antagonism, analgesic and sedative properties rooted in centuries of traditional Chinese medicine use, and an emerging clinical research profile in substance use disorders, neuropathic pain, and neuropsychiatric applications.

    Abstract

    Tetrahydropalmatine (THP), also known as rotundine, is a tetrahydroprotoberberine isoquinoline alkaloid isolated from tubers of Corydalis yanhusuo (Yan Hu Suo) and roots of Stephania rotunda, two genera of the Papaveraceae and Menispermaceae families with extensive histories in traditional Chinese and Southeast Asian medicine. The compound exists as two enantiomers: levo-tetrahydropalmatine (l-THP, the 13aR configuration) and dextro-tetrahydropalmatine (d-THP, the 13aS configuration), as well as the racemic mixture (dl-THP). The levorotatory enantiomer is the principal pharmacologically active form and has been manufactured as a pharmaceutical product in China under the name rotundine for the treatment of pain and insomnia since the mid-twentieth century. Molecular pharmacology studies have established that l-THP acts as a moderate-affinity antagonist at dopamine D1 receptors (Ki approximately 124 nM), dopamine D2 receptors (Ki approximately 388 nM), and dopamine D3 receptors, with additional binding at serotonin 5-HT1A receptors (Ki approximately 340 nM), alpha-1 adrenergic receptors, and modulatory effects on GABAergic neurotransmission through enhancement of GABA-A receptor activity. This multi-target monoaminergic profile distinguishes tetrahydropalmatine from conventional dopamine antagonists and underwrites the compound’s diverse pharmacological actions: analgesia in inflammatory and neuropathic pain models, sedation and anxiolysis, attenuation of drug-seeking behavior in cocaine, heroin, and nicotine self-administration paradigms, and anti-inflammatory activity through suppression of NF-kappaB signaling and proinflammatory cytokine release.

    Pharmacokinetics in humans are characterized by rapid absorption (absorption half-life approximately 0.5 hours), rapid distribution (distribution half-life approximately 0.74 hours), and slow elimination (elimination half-life approximately 11.4 hours). Oral bioavailability is low due to extensive first-pass hepatic metabolism, principally through CYP3A and CYP1A2 isoforms, with stereoselective differences between enantiomers. Self-microemulsifying drug delivery systems have demonstrated a 3.25-fold improvement in relative bioavailability compared with conventional suspension formulations. The compound crosses the blood-brain barrier and achieves central nervous system concentrations sufficient for dopaminergic and serotonergic receptor modulation at therapeutic oral doses.

    Clinical evidence is modest but growing. A randomized, double-blind, placebo-controlled Phase 1 study in cocaine users (2016) established the safety and tolerability of a 3.5-day oral l-THP course. A pilot clinical study in heroin-dependent patients demonstrated that one-month l-THP treatment significantly reduced opiate craving and enhanced the abstinence rate three-fold at three months post-discharge. A randomized controlled trial of l-THP as adjunctive treatment for schizophrenia (NCT02118610, published 2020) did not demonstrate significant improvement in psychiatric symptoms at 30 mg twice daily for four weeks, though the study confirmed tolerability and absence of serious adverse events. The compound has been marketed as a sedative-analgesic in China for decades and is under active investigation in the United States and Vietnam for substance use disorders.

    The principal safety signals are sedation (dose-dependent, reflecting the composite dopaminergic and GABAergic mechanism), hepatotoxicity (reported in association with herbal preparations containing l-THP, though causality is confounded by product adulteration and polypharmacy), and rare acute poisoning characterized by mild neurological disturbance with rapid recovery. This monograph documents the chemistry, stereochemistry, and natural sources of tetrahydropalmatine; the multi-receptor pharmacology in molecular and behavioral detail; the pharmacokinetic record including CYP isoform involvement and bioavailability optimization; the preclinical pharmacology across pain, addiction, neuroinflammation, and neuroprotection models; the clinical evidence base; sourcing and quality verification; reconstitution and handling; stack interactions; adverse events and safety signal; and a comparative assessment of five alternative analgesic or dopaminergic compounds against tetrahydropalmatine on five competency standards.

    Read the full monograph

    The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

    KDC-MN-1616Open in new tab →

    Download PDF →

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

  • Atremorine

    Vicia faba-derived dopaminergic bioproduct with natural L-DOPA donor activity and neuroprotective properties

    A standardized biopharmaceutical extract (E-PodoFavalin-15999) obtained by non-denaturing biotechnological procedures from structural components of Vicia faba L., functioning as a potent dopaminergic enhancer, natural L-DOPA donor, and neuroprotective agent for the prevention and treatment of Parkinsonian disorders, with genotype-dependent catecholaminergic and hormonal modulation.

    Abstract

    Atremorine (E-PodoFavalin-15999) is a novel biopharmaceutical product obtained by non-denaturing biotechnological processing of structural components of Vicia faba L. (the broad bean or fava bean), developed at the EuroEspes Biomedical Research Center (now International Center of Neuroscience and Genomic Medicine, Bergondo, A Coruna, Spain) under the direction of Ramon Cacabelos for the prevention and treatment of Parkinson’s disease (PD) and related dopamine-dependent disorders. Unlike synthetic levodopa (L-DOPA) formulations, Atremorine is a complex bioproduct containing a standardized concentration of approximately 25 mg of natural L-DOPA per gram of product, together with vegetal proteins, unsaturated fatty acids, minerals, vitamins, vegetal fiber, starch, carotenoid pigments, and phytosterols, all of which are proposed to contribute synergistically to its pharmacological activity and to confer neuroprotective properties absent from purified synthetic L-DOPA.

    Preclinical studies in cell culture (human neuroblastoma SH-SY5Y cells, hippocampal slices under oxygen-glucose deprivation, striatal slices under 6-hydroxydopamine-induced neurotoxicity) and in animal models (MPTP-induced parkinsonism in mice) have demonstrated that Atremorine protects dopaminergic neurons against neurotoxic insult, inhibits microglial activation, and improves motor function [1, 2, 3]. Clinical studies in over 600 Parkinson’s disease patients have confirmed that Atremorine is a potent enhancer of catecholaminergic neurotransmission: a single 5 g oral dose produces a dramatic increase in plasma dopamine levels within one hour, with over 97 percent of patients responding [4, 5]. In drug-free PD patients, plasma dopamine levels increase from approximately 12 pg/mL to approximately 6,463 pg/mL; in patients receiving conventional antiparkinsonian therapy, dopamine levels increase from approximately 1,322 pg/mL to approximately 16,029 pg/mL, indicating substantial potentiation of conventional dopaminergic pharmacotherapy [5, 6]. The dopamine response is accompanied by significant changes in circulating catecholamines (adrenaline, noradrenaline) and in dopamine-regulated hormones (reductions in prolactin, cortisol, and growth hormone), with no significant effect on serotonin or histamine levels [4].

    The variability in the Atremorine-induced dopamine response is highly attributable to pharmacogenetic factors. Polymorphic variants in pathogenic genes (notably APOE), metabolic genes (CYP2D6, CYP2C9, CYP2C19, CYP3A4/5), and neurotransmitter transporter genes (SLC6A3/DAT, SLC6A2/NET, SLC6A4/SERT) exert genotype-dependent effects on the magnitude of the dopamine response [5, 7, 8]. APOE-3 carriers are the best responders and APOE-4 carriers are the worst; CYP2D6 normal metabolizers respond most strongly and CYP2D6 poor metabolizers respond least [5, 7]. Atremorine also exerts epigenetic activity, increasing global DNA methylation in both transgenic Alzheimer’s disease mice (3xTg model) and in PD patients, with upregulation of the de novo DNA methyltransferase DNMT3a [9]. The coadministration of Atremorine with conventional antiparkinsonian drugs allows dose reduction of the conventional agents by 25 to 50 percent, with enhancement of clinical benefits and reduction of short- and long-term adverse drug reactions [5, 6]. The compound is covered by European Patent EP3225245A1 and related filings. It is not approved by any major regulatory authority as a pharmaceutical; it is classified and distributed as a bioproduct or nutraceutical. This monograph reviews the composition, extraction, neuroprotective pharmacology, clinical dopaminergic evidence, pharmacogenomic determinants of response, handling, stack interactions, safety profile, and comparative positioning of Atremorine against five alternative dopaminergic and neuroprotective interventions for Parkinson’s disease.

    Read the full monograph

    The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

    KDC-MN-1617Open in new tab →

    Download PDF →

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

  • CT1812

    Selective sigma-2 receptor (TMEM97) complex antagonist with anti-amyloid-beta oligomer synaptoproctective activity

    A first-in-class, orally bioavailable isoindoline sigma-2 receptor antagonist developed by Cognition Therapeutics to displace amyloid-beta oligomers from neuronal synapses, with Phase 2 clinical evidence of cognitive benefit in Alzheimer’s disease and dementia with Lewy bodies.

    Abstract

    CT1812 (zervimesine; CAS 1802632-22-9) is a first-in-class, orally bioavailable small-molecule antagonist of the sigma-2 receptor complex (also designated TMEM97, transmembrane protein 97) developed by Cognition Therapeutics for the treatment of Alzheimer’s disease (AD), dementia with Lewy bodies (DLB), and geographic atrophy secondary to dry age-related macular degeneration. The compound was identified through a phenotypic neuronal screening assay designed to detect reversal of amyloid-beta oligomer (ABO) induced synaptotoxicity and was chemically optimized from a series of isoindoline scaffolds selected for central nervous system penetration, metabolic stability, and selectivity against cardiac ion channel (hERG) liability. CT1812 binds the sigma-2 receptor with a Ki of 8.5 nM and demonstrates greater than 100-fold selectivity over a broad receptor panel, with approximately 10-fold selectivity over the sigma-1 receptor. The mechanism of action is allosteric antagonism of the sigma-2 receptor complex, which includes TMEM97, progesterone receptor membrane component 1 (PGRMC1), and low-density lipoprotein receptor (LDLR) at the neuronal surface. Engagement of this complex by CT1812 induces a conformational change that displaces prebound amyloid-beta oligomers from synaptic receptors without affecting oligomer assembly or dissociation, thereby restoring synaptic trafficking, reducing synaptotoxicity, and facilitating clearance of oligomers into the cerebrospinal fluid.

    In preclinical studies, CT1812 demonstrated robust brain penetration (brain-to-plasma ratio of 5.7 at 24 hours; unbound brain-to-plasma partition coefficient Kp,uu of 6.75), achieved greater than 84 percent sigma-2 receptor occupancy at therapeutically relevant doses, and improved cognitive performance in transgenic Alzheimer’s mouse models across Y-maze, Morris water maze, and fear conditioning paradigms. The compound is not a P-glycoprotein substrate, exhibits favorable oral absorption with time to peak plasma concentration of 1 to 2 hours and a plasma elimination half-life of approximately 12 hours in humans, and is metabolized primarily by CYP3A4 with secondary contributions from CYP2D6 and CYP2C19.

    A Phase 1 trial in 80 healthy volunteers established safety and tolerability at single doses up to 1120 mg and multiple doses up to 840 mg daily for 14 days, with dose-proportional pharmacokinetics and cerebrospinal fluid penetration achieving estimated receptor occupancy of 97 to 98 percent. A Phase 1b/2 trial (COG0102) in 19 patients with mild to moderate AD demonstrated reductions in cerebrospinal fluid synaptic damage markers (neurogranin and synaptotagmin-1) and decreases of 30 percent or more in six tau phosphorylation sites after 28 days of treatment. The Phase 2 SHINE trial (COG0201) enrolled 153 patients with mild to moderate AD randomized to 100 mg, 300 mg, or placebo for 182 days; the 100 mg dose produced a 39 percent reduction in ADAS-Cog 11 decline relative to placebo, with a 95 percent slowing of cognitive decline in the subpopulation with baseline plasma p-tau217 below the median. The Phase 2 SHIMMER trial (COG1201) enrolled 130 patients with mild to moderate DLB and met its primary safety endpoint; secondary analyses showed 82 percent of treated patients demonstrated slowing on the total Neuropsychiatric Inventory, with a 91 percent reduction in decline of attentional fluctuation measures. CT1812 has also been evaluated in the Phase 2 MAGNIFY trial for geographic atrophy, where treated patients showed 28.6 percent slower lesion growth over 18 months compared to placebo. The compound is generally well tolerated; the principal adverse events are headache, gastrointestinal symptoms (nausea, diarrhea, constipation), and, at the 300 mg dose in SHINE, transient elevations in liver function tests that resolved upon drug discontinuation. CT1812 is positioned for Phase 3 development in Alzheimer’s disease. This monograph reviews the compound identification, discovery and development history, molecular pharmacology, pharmacokinetics, preclinical and clinical evidence, sourcing, reconstitution, stack interactions, safety profile, and a comparative assessment of five alternative approaches to amyloid-beta oligomer or sigma-2 receptor pharmacology.

    Read the full monograph

    The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

    KDC-MN-1570Open in new tab →

    Download PDF →

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

  • Mirogabalin

    Selective alpha-2-delta-1 subunit ligand of voltage-gated calcium channels (gabapentinoid)

    A next-generation gabapentinoid developed by Daiichi Sankyo with preferential binding and prolonged dissociation kinetics at the alpha-2-delta-1 subunit of voltage-gated calcium channels, approved in Japan and select Asian jurisdictions for peripheral neuropathic pain and distinguished from pregabalin and gabapentin by subunit selectivity and a potentially wider therapeutic margin.

    Abstract

    Mirogabalin (DS-5565) is a novel gabapentinoid analgesic that binds with high affinity and selectivity to the alpha-2-delta-1 (alpha2delta-1) subunit of voltage-gated calcium channels (VGCCs), developed by Daiichi Sankyo Company and approved in Japan in January 2019 for the treatment of peripheral neuropathic pain associated with diabetic peripheral neuropathy (DPNP) and postherpetic neuralgia (PHN). The compound is marketed as Tarlige in oral tablet formulation and has subsequently received regulatory approval in Taiwan (2020) and Thailand (2022) for peripheral neuropathic pain indications. Unlike the first-generation gabapentinoids gabapentin and pregabalin, which bind nonselectively to both alpha2delta-1 and alpha2delta-2 subunits with comparable affinity and dissociation kinetics, mirogabalin demonstrates preferential binding to the alpha2delta-1 subunit with a dissociation half-life of approximately 11.1 hours at alpha2delta-1 versus 2.4 hours at alpha2delta-2 in human recombinant systems. This kinetic selectivity is hypothesized to confer a favorable ratio of analgesic efficacy (mediated principally through alpha2delta-1 in dorsal root ganglia and spinal cord dorsal horn) to central nervous system adverse effects (mediated in part through alpha2delta-2 in cerebellar Purkinje neurons and other central structures), although this hypothesis has not been formally validated in controlled comparative clinical trials against pregabalin at equipotent analgesic doses.

    The clinical development program for mirogabalin comprises two pivotal Phase 3 randomized, double-blind, placebo-controlled trials in Asian patients with DPNP (834 patients) and PHN (765 patients), both of which demonstrated statistically significant reductions in average daily pain scores at week 14 relative to placebo across multiple dose groups (15 mg once daily, 10 mg twice daily, and 15 mg twice daily). A separate Phase 3 program evaluated mirogabalin for central neuropathic pain after spinal cord injury in a multinational Asian trial. In contrast, the global Phase 3 ALDAY program for fibromyalgia pain, consisting of three large randomized trials enrolling more than 3,600 subjects in the United States and Europe, failed to meet the primary efficacy endpoint in all three studies; mirogabalin did not demonstrate statistically significant superiority over placebo for reduction in worst daily pain score at week 13 in fibromyalgia, and the fibromyalgia development program was subsequently discontinued. The compound is not approved by the United States Food and Drug Administration or the European Medicines Agency.

    Pharmacokinetically, mirogabalin is rapidly and nearly completely absorbed after oral administration with a time to peak plasma concentration of approximately 1 hour. The compound undergoes limited hepatic metabolism (13 to 20 percent of administered dose) through uridine 5-prime-diphospho-glucuronosyltransferase (UGT) isoforms, with the majority of the dose (61 to 72 percent) excreted unchanged in urine. Renal clearance exceeds glomerular filtration rate, indicating active tubular secretion. Dose adjustment is required in patients with renal impairment. The principal adverse events are somnolence, dizziness, peripheral edema, and weight gain, consistent with the gabapentinoid class but reported at generally lower incidence than pregabalin at comparable analgesic doses in some observational comparisons.

    This monograph reviews the chemistry and structural pharmacology of mirogabalin; the alpha2delta subunit binding characteristics and dissociation kinetics that distinguish the compound from pregabalin and gabapentin; the complete pharmacokinetic record; the preclinical analgesic pharmacology in neuropathic and inflammatory pain models; the clinical evidence base across peripheral neuropathic, central neuropathic, and fibromyalgia indications; sourcing and quality verification considerations; reconstitution and handling; stack interactions; adverse-event signal; and a comparative assessment of five alternative analgesic candidates against mirogabalin on five competency standards.

    Read the full monograph

    The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

    KDC-MN-1598Open in new tab →

    Download PDF →

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

  • Pyrilutamide

    Nonsteroidal antiandrogen; selective, silent androgen receptor antagonist of the thiohydantoin structural class

    A topical nonsteroidal antiandrogen developed by Kintor Pharmaceuticals as a first-in-class selective silent antagonist of the androgen receptor for the treatment of androgenetic alopecia and acne vulgaris, distinguished from oral 5-alpha-reductase inhibitors by receptor-level blockade with minimal systemic exposure.

    Abstract

    Pyrilutamide (developmental code KX-826) is a nonsteroidal antiandrogen of the thiohydantoin structural class under clinical development by Suzhou Kintor Pharmaceuticals for the topical treatment of androgenetic alopecia (AGA) and acne vulgaris. The compound acts as a selective, high-affinity silent antagonist of the androgen receptor (AR), competitively displacing dihydrotestosterone (DHT) and testosterone from the ligand-binding domain without inducing any agonist-mediated transcriptional activity. This mechanism distinguishes pyrilutamide from systemic 5-alpha-reductase inhibitors (finasteride, dutasteride) that reduce circulating DHT concentrations, and from first-generation nonsteroidal antiandrogens (bicalutamide, flutamide) that possess residual partial agonist activity and are administered systemically. In cell-based AR transactivation assays, pyrilutamide exhibits an IC50 of approximately 0.28 nM, a Ki of 24 nM in competitive AR binding assays (compared to 48 nM for enzalutamide), and an IC50 of 264 nM for inhibition of prostate-specific antigen secretion in LNCaP prostate cancer cells, establishing it as one of the most potent topical antiandrogens characterized to date.

    The compound was designed for topical delivery to the scalp and skin, with molecular properties selected to favor dermal retention and limit transdermal penetration. Preclinical pharmacokinetic evaluation in rats demonstrated rapid distribution to skin and adipose tissue following topical application, with low transdermal bioavailability and negligible plasma exposure. In human clinical studies, peak plasma concentrations following application of the 0.5% topical formulation remained below 0.5 ng/mL, with an estimated dermal half-life of approximately 2 hours. Toxicological assessments established no-observed-adverse-effect levels (NOAELs) of greater than 5000 mg/kg orally in rats and 90 mg/kg dermally in minipigs, yielding systemic safety margins of 168- to 222-fold over levels associated with therapeutic efficacy.

    Clinical development of pyrilutamide has proceeded through multiple trials across China and the United States. A Phase I ascending-dose safety study in 40 men in the United States (0.3% to 9.6% concentrations) demonstrated tolerability with only mild contact dermatitis as the principal adverse event. A Phase II randomized, placebo-controlled trial in 120 Chinese men with androgenetic alopecia (Norwood grades 3V, 4, and 5) reported that 0.5% pyrilutamide applied twice daily for 24 weeks produced a mean increase of 22.73 hairs per square centimeter in target area hair count (TAHC) from baseline, representing a 15.34 hairs per square centimeter advantage over placebo. A Phase II trial in Chinese women with female-pattern hair loss met its primary endpoint. A subsequent pivotal Phase III trial in Chinese men, however, failed to demonstrate statistical significance on the primary TAHC endpoint versus placebo at 24 weeks (announced November 2023). Long-term safety extensions at 52 weeks reported that 46% of patients achieved at least a 10 hairs per square centimeter increase and 20% achieved at least a 20 hairs per square centimeter increase, with no drug-related sexual dysfunction and a favorable overall safety profile. A reformulated 1.0% tincture is now under evaluation in a Phase II/III pivotal trial initiated in 2025, with enrollment exceeding 750 participants at more than 20 hospital sites. A Phase II trial for acne vulgaris has completed enrollment in China. No regulatory approval has been granted in any jurisdiction as of the date of this monograph.

    This monograph reviews the chemistry, structural class, and synthesis of pyrilutamide; the androgen receptor antagonist mechanism in molecular detail; the topical pharmacokinetic profile including systemic exposure characterization; the preclinical pharmacology in androgen-driven disease models; the clinical evidence base across androgenetic alopecia in men and women, acne vulgaris, and related dermatological indications; sourcing and quality verification considerations for research-grade material; reconstitution and handling; stack-interaction considerations with other dermatological and hormonal agents; the adverse-event and safety signal; and a comparative assessment of five alternative agents (finasteride, dutasteride, topilutamide, RU-58841, and minoxidil) against pyrilutamide on five competency standards (novelty, effect size, promising potential, side-effect profile, and overall validation).

    Read the full monograph

    The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

    KDC-MN-1619Open in new tab →

    Download PDF →

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

  • Baclofen

    Selective GABA-B receptor agonist with centrally and spinally mediated inhibitory activity

    A chlorophenyl-substituted gamma-aminobutyric acid analog developed at Ciba-Geigy as an antiepileptic candidate, repositioned as the prototypical GABA-B receptor agonist for the treatment of spasticity, and subsequently investigated for alcohol use disorder, gastroesophageal reflux, and neurodevelopmental conditions.

    Abstract

    Baclofen (4-amino-3-(4-chlorophenyl)butanoic acid) is a lipophilic analog of gamma-aminobutyric acid (GABA) and the only clinically approved selective agonist of the GABA-B metabotropic receptor. Synthesized at Ciba-Geigy by Heinrich Keberle in 1962 as a candidate antiepileptic agent, the compound failed to demonstrate meaningful anticonvulsant activity in human trials but was found to reduce skeletal muscle spasticity through inhibition of monosynaptic and polysynaptic spinal reflexes. This observation led to regulatory approval in the United Kingdom in 1971 and by the United States Food and Drug Administration in 1977 for the treatment of spasticity of spinal origin, including that associated with multiple sclerosis and spinal cord injury. The introduction of intrathecal baclofen delivery by programmable pump in 1984, pioneered by Richard Penn and colleagues at Rush University, extended the therapeutic range to severe, refractory spasticity of both spinal and cerebral origin, including cerebral palsy and acquired brain injury; the intrathecal formulation received FDA approval in 1992.

    The molecular pharmacology of baclofen is dominated by agonism at the GABA-B receptor, a heterodimeric G-protein-coupled receptor composed of GABA-B1 and GABA-B2 subunits that signals through Gi/Go proteins to activate inwardly rectifying potassium channels, inhibit voltage-gated calcium channels, and reduce adenylyl cyclase activity. These actions produce presynaptic inhibition of excitatory neurotransmitter release and postsynaptic hyperpolarization in the spinal cord, brainstem, and higher brain regions. Baclofen is marketed as a racemic mixture; the (R)-enantiomer (arbaclofen) is approximately 100-fold more potent than the (S)-enantiomer at the GABA-B receptor and is responsible for essentially all pharmacological activity. Pharmacokinetics after oral administration are characterized by rapid absorption (bioavailability 70 to 85 percent), peak plasma concentrations at 2 to 3 hours, minimal hepatic metabolism (approximately 15 percent, primarily by deamination), predominant renal excretion of unchanged drug (70 to 80 percent), and a short plasma elimination half-life of 2 to 4 hours that necessitates multiple daily dosing.

    Beyond the registered spasticity indication, baclofen has been investigated extensively in alcohol use disorder, where GABA-B receptor agonism in the mesolimbic dopamine pathway reduces ethanol-seeking behavior and withdrawal severity. Sixteen randomized controlled trials have been conducted since the initial Addolorato et al. (2002) demonstration, with results that are encouraging but inconsistent across dose ranges and populations; France approved baclofen for alcohol dependence on a temporary basis in 2014. Additional research applications include gastroesophageal reflux disease (reduction of transient lower esophageal sphincter relaxations through GABA-B agonism on vagal afferents), trigeminal neuralgia, hiccups, and the R-enantiomer (arbaclofen) in autism spectrum disorder and fragile X syndrome. The compound has a well-characterized adverse-event profile dominated by sedation, drowsiness, and muscular weakness at therapeutic doses, with a clinically significant withdrawal syndrome (agitation, seizures, hyperthermia, rhabdomyolysis) on abrupt discontinuation and a toxicity profile in overdose that includes coma, respiratory depression, and paradoxical seizures. This monograph reviews the chemistry, synthesis, and stereochemistry of baclofen; the GABA-B receptor pharmacology in molecular detail; the comprehensive human pharmacokinetic record; the clinical evidence base across spasticity, alcohol use disorder, gastroesophageal reflux, and investigational indications; the reconstitution, sourcing, and stack-interaction considerations for laboratory and clinical work; and a comparative assessment of five alternative antispasticity and GABA-B-active compounds against baclofen on five competency standards (novelty, effect size, promising potential, side-effect profile, and overall validation).

    Read the full monograph

    The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

    KDC-MN-1567Open in new tab →

    Download PDF →

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.